about
A controlled, longitudinal study of dementia in Parkinson's disease.Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment.Distribution of beta-endorphin in normal and schizophrenic human brains.Huntington's chorea: post mortem activity of enzymes involved in cerebral glucose metabolism.Differential effects of agonal status on measurements of GABA and glutamate decarboxylase in human post-mortem brain tissue from control and Huntington's chorea subjects.Vasoactive intestinal polypeptide (VIP): distribution in normal human brain and in Huntington's disease.Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington's disease and after intrastriatal kainic acid in rats.Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness.Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia.Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human post-mortem brain tissue.3H-Spiperone binding in normal and schizophrenic post-mortem human brain.Intravenous immunoglobulin in the Guillain-Barré syndrome. May cause severe adverse skin reactions.Cell implantation in Parkinson's disease.Cognitive impairment and dementia in Parkinson's disease: a controlled study.Brain norepinephrine and dopamine in schizophrenia.Reduction of angiotensin-converting enzyme in substantia nigra in early-onset schizophrenia.Post-mortem stability of dopamine, glutamate decarboxylase and choline acetyltransferase in the mouse brain under conditions simulating the handling of human autopsy material.Human post-mortem pineal enzyme activity.The evolution and profile of dementia in Parkinson's disease.Mortality in Parkinson's disease and its association with dementia and depression.A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.Dopamine and homovanillic acid concentrations in the post-mortem brain in schizophrenia [proceedings]A controlled study of dementia in Parkinson's disease over 54 monthsDopaminergic abnormalities in postmortem schizophrenic brain
P50
Q36964811-71E96F2C-EBCE-4C1D-B3E1-90D28E870759Q39266144-F2D02927-6752-41ED-B73B-63F7837AD190Q39704313-41E85AB9-9CDE-46BB-9A10-12183C310159Q39825195-C37DD3FC-525A-4740-8316-B0D43CD1CB3CQ39893974-CD5E40ED-4A5C-46B3-B01F-A97C02A2CF27Q39895578-20E12374-E3DF-425F-87AF-73EF90EECDBAQ40189041-43CAA784-AED7-42BB-928D-39F90BCA669FQ40217476-8DE0FC57-C721-40A0-BB45-7D1C7C51D952Q41026526-C74B3A26-F16E-43F6-AFCE-C84F0DE52F60Q41530863-932B56D6-F5EC-46FA-AC7C-AC5B27F69291Q41671753-F6424E74-9A70-48D9-BAD5-65426FF8B4EBQ41970620-C913FB26-024C-4A13-B736-6FEB6536308DQ43190964-2CEA9040-6405-4014-99CF-17F60C4A1562Q43416444-EB57155B-509A-4FE4-BCB5-F580FF5856BAQ44494550-7B2913BF-5B39-45C9-8145-92100A592D18Q48089854-5CDB49B7-C08C-48F6-8C7D-92CD47D8ED4FQ48102000-0832B0AC-8226-4BBF-B225-AD39274E2A0CQ48177808-4EE59EF2-D344-4DA7-80C4-51E18BB316EAQ50591500-DE01CF87-3940-4FD2-9E60-36A82BF4A071Q51118962-FA226B01-4399-4E34-9AF9-42E1EA580756Q52859006-5F850873-C907-4EA3-8D28-6CE3A27C666DQ52864240-3C7185EA-F86B-4635-A1F1-B686D9D13CFFQ66962693-73D23702-B1E2-4BD1-9448-4E894F0E4BC0Q70529438-A8E22F0E-4330-4152-B2DE-C350DAD238D1Q71286053-809765B6-C2F8-49BB-85E5-F721C5CCC987
P50
name
Ernest G. S. Spokes
@en
type
label
Ernest G. S. Spokes
@en
altLabel
E G S Spokes
@en
E. G. S. Spokes
@en
EGS Spokes
@en
Ernest G S Spokes
@en
Ernest G Spokes
@en
Ernest G. Spokes
@en
Ernest Spokes
@en
Spokes E
@en
Spokes E. G. S.
@en
Spokes E. G.
@en
prefLabel
Ernest G. S. Spokes
@en